GailLTorkildsenMD

Ophthalmology • Andover, MA

Physician

Join to view full profile

Dr. Torkildsen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Torkildsen's full profile

Already have an account?

Office
138 Haverhill St
Suite 104
Andover, MA 01810
Phone+1 978-475-0705

Fax+1 978-475-0008

Summary

Dr. Gail Torkildsen, based in Andover, MA, specializes in Ophthalmology, with a focus on bacterial conjunctivitis, allergic conjunctivitis, and dry eye. She received her medical degree from the University of Pittsburgh School of Medicine in 1992 and completed her ophthalmology residency from 1994 to 1997 at the Icahn School of Medicine at Mount Sinai/New York Eye and Ear Infirmary at Mount Sinai. Prior to that, she did a surgery residency from 1992 to 1994 at UPMC Medical Education in Pittsburgh. She has published research in prominent journals, mostly surrounding treatments for dry eye disease. She has also been active in clinical trials, primarily revolving around the safety and efficacy of various ophthalmic solutions for dry eye syndrome.

Education & Training

Icahn School of Medicine at Mount Sinai/New York Eye and Ear Infirmary at Mount SinaiResidency, Ophthalmology, 1994 - 1997
UPMC Medical Education (Pittsburgh)Residency, Surgery, 1992 - 1994
University of Pittsburgh School of MedicineClass of 1992

Certifications & Licensure

FL State Medical License 2002 - 2026
MA State Medical License 1997 - 2025
MD State Medical License 2002 - 2003
American Board of Ophthalmology Ophthalmology

Clinical Trials

Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye Start of enrollment: 2005 Nov 01
Completed
Phase 2
Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model Start of enrollment: 2008 May 01
Completed
Phase 4
Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Dry Eye Start of enrollment: 2008 Oct 01
Completed
Phase 2
Safety and Efficacy Study of RX-10045 on the Signs and Symptoms of Dry Eye Start of enrollment: 2008 Nov 01
Completed
Phase 2
Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis Start of enrollment: 2009 Feb 01
Completed
Phase 2
Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis Start of enrollment: 2009 Apr 24
Completed
Phase 2
A Study Evaluating the Efficacy of SAR 1118 (0.1%, 1.0%, 5.0%) Ophthalmic Solution in Subjects With Dry Eye Conducted in a Controlled Adverse Environment (CAE) Start of enrollment: 2009 Aug 03
Completed
Phase 2
A Pilot Study of the Safety of MC-1101 in Both Normal Volunteers and Patients With Early Dry AMD Start of enrollment: 2009 Aug 01
Completed
Phase 1
Safety and Efficacy Study of EGP-437 (Dexamethasone Phosphate Formulated for Ocular Iontophoresis) to Treat Dry Eye Start of enrollment: 2010 Jun 01
Completed
Phase 3
Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye Start of enrollment: 2010 Nov 01
Completed
Phase 2
Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model Start of enrollment: 2012 Nov 01
Completed
Phase 4
A Phase 2, Open-Label, Randomized, Parallel Group, Placebo-Controlled, Single-Center Study to Assess Anti-microbial Efficacy and Safety of DCN01 Compared to Unisol® Following Topical Periocular Administration in Healthy Volunteers Start of enrollment: 2013 Apr 01
Completed
Phase 2
Safety and Efficacy of PG101 for Dry Eye Syndrome Start of enrollment: 2013 Dec 01
Completed
Phase 1, Phase 2
A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES) Start of enrollment: 2014 Apr 01
Completed
Phase 2
Efficacy and Safety of XG-104 for the Treatment of Dry Eye Start of enrollment: 2014 Sep 01
Completed
Phase 2
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2 Start of enrollment: 2016 Nov 01
Completed
Phase 3
A Study to Assess Efficacy of HL036 in Subjects With Dry Eyes Start of enrollment: 2017 Nov 05
Completed
Phase 2
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3 Start of enrollment: 2019 May 24
Completed
Phase 3
Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution Start of enrollment: 2023 Apr 20
Completed
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

5 citations
Efficacy and Safety of the Melanocortin Pan-Agonist PL9643 in a Phase 2 Study of Patients with Dry Eye Disease.
David Evans, Kenneth Kenyon, George Ousler, Michael Watson, Patrick Vollmer
Journal of Ocular Pharmacology and Therapeutics. 2023-11-01
24 citations
ONSET-1 Phase 2b Randomized Trial to Evaluate the Safety and Efficacy of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease.
David Wirta, Gail L Torkildsen, Blair Boehmer, David A Hollander, Edward Bendert
Cornea. 2022-10-01
5 citations
Efficacy and Safety of Single-dose OC-02 (Simpinicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The PEARL Phase II Randomized Trial.
Gail L Torkildsen, Guruprasad R Pattar, Gary Jerkins, Kristen Striffler, Jeffrey Nau
Clinical Therapeutics. 2022-09-01

Press Mentions

China’s Professor Lixin Xie Leads Dry Eye Treatment Study at Qingdao Eye HospitalOctober 15th, 2019
Novaliq Announces Last Patient Enrolled in Phase 2 Clinical Trial of CyclASol® for the Treatment of Moderate to Severe Dry Eye DiseaseMay 6th, 2016
Pour Le Traitement Du Syndrome De L'oeil Sec Modéré à GraveMay 6th, 2016

GailLTorkildsenMD

Dr. Torkildsen is on Doximity

Summary

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.